{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:14:47Z","timestamp":1778494487164,"version":"3.51.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-18-0178"],"award-info":[{"award-number":["APVV-18-0178"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Health Care and Philos"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11019-020-09958-z","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T16:02:23Z","timestamp":1590681743000},"page":"485-496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Compassionate use of psychedelics"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-1978","authenticated-orcid":false,"given":"Adam","family":"Greif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"\u0160urkala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"9958_CR1","unstructured":"Abrahart, D. 1998. A Critical Review of Theories and Research Concerning Lysergic Acid Diethylamide (LSD) and Mental Health [Unpublished master's thesis]. University of Portsmouth. Accessed 28 November 2019, from https:\/\/maps.org\/research-archive\/html_bak\/abrahart.html."},{"issue":"27","key":"9958_CR2","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1200\/JCO.2006.06.0269","volume":"24","author":"M Agrawal","year":"2006","unstructured":"Agrawal, M., C. Grady, D.L. Fairclough, N.J. Meropol, K. Maynard, and E.J. Emanuel. 2006. Patients\u2019 Decision-Making Process Regarding Participation in Phase I Oncology Research. Journal of Clinical Oncology 24 (27): 4479\u20134484. https:\/\/doi.org\/10.1200\/JCO.2006.06.0269.","journal-title":"Journal of Clinical Oncology"},{"key":"9958_CR3","doi-asserted-by":"publisher","unstructured":"Borysowski, J., H. Ehni, and A. G\u00f3rski. 2017. Ethics Review in Compassionate Use. BMC Medicine. https:\/\/doi.org\/10.1186\/s12916-017-0910-9.","DOI":"10.1186\/s12916-017-0910-9"},{"key":"9958_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2019.04.008","volume":"65","author":"J Borysowski","year":"2019","unstructured":"Borysowski, J., and A. G\u00f3rski. 2019. Compassionate Use of Unauthorized Drugs: Legal Regulations and Ethical Challenges. European Journal of Internal Medicine 65: 12\u201316. https:\/\/doi.org\/10.1016\/j.ejim.2019.04.008.","journal-title":"European Journal of Internal Medicine"},{"key":"9958_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neubiorev.2018.02.004","volume":"87","author":"JC Bouso","year":"2018","unstructured":"Bouso, J.C., R.G. dos Santos, M.\u00c1. Alc\u00e1zar-C\u00f3rcoles, and J.E.C. Hallak. 2018. Serotonergic Psychedelics and Personality: A Systematic Review of Contemporary Research. Neuroscience & Biobehavioral Reviews 87: 118\u2013132. https:\/\/doi.org\/10.1016\/j.neubiorev.2018.02.004.","journal-title":"Neuroscience & Biobehavioral Reviews"},{"issue":"4","key":"9958_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/jpm.2017.0684","volume":"21","author":"I Byock","year":"2018","unstructured":"Byock, I. 2018. Taking Psychedelics Seriously. Journal of Palliative Medicine 21 (4): 417\u2013421. https:\/\/doi.org\/10.1089\/jpm.2017.0684.","journal-title":"Journal of Palliative Medicine"},{"issue":"7","key":"9958_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R.L., M. Bolstridge, J. Ruckner, C.M.J. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, J.A. Rickard, B. Forbes, A. Feilding, D. Taylor, S. Pilling, V.H. Curran, and D. Nutt. 2016a. Psilocybin with Psychological Support for Treatment-Resistant Depression: An Open-Label Feasibility Study. Lancet Psychiatry 3 (7): 619\u2013627. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7.","journal-title":"Lancet Psychiatry"},{"issue":"117","key":"9958_CR8","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R.L., S. Muthukumaraswamy, L. Roseman, M. Kaelen, W. Droog, K. Murphy, E. Tagliazucchi, E.E. Schenberg, T. Nest, C. Orban, R. Leech, L.T. Williams, T.M. Williams, M. Bolstridge, B. Sessa, J. McGonigle, M.I. Sereno, D. Nichols, P.J. Hellyer, P. Hobden, J. Evans, K.D. Singh, R.G. Wise, H.V. Curran, A. Feilding, and D.J. Nutt. 2016b. Neural Correlates of the LSD Experience Revealed by Multimodal Neuroimaging. Proceedings of the National Academy of Sciences 113 (117): 4853\u20134858. https:\/\/doi.org\/10.1073\/pnas.1518377113.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"9958_CR9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R.L., and G.M. Goodwin. 2017. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology 42 (11): 2105\u20132113. https:\/\/doi.org\/10.1038\/npp.2017.84.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"9958_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00005053-196001000-00005","volume":"130","author":"S Cohen","year":"1960","unstructured":"Cohen, S. 1960. Lysergic Acid Diethylamide: Side-Effects and Complications. Journal of Nervous and Mental Disease 130 (1): 33\u201340. https:\/\/doi.org\/10.1097\/00005053-196001000-00005.","journal-title":"Journal of Nervous and Mental Disease"},{"key":"9958_CR11","unstructured":"COMPASS. 2018. COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-Resistant Depression [Blog Post]. October 23 Accessed 28 November 2019, from https:\/\/compasspathways.com\/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression\/."},{"key":"9958_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1056\/NEJMhle1409465","volume":"372","author":"JJ Darrow","year":"2015","unstructured":"Darrow, J.J., A. Sarpatwari, J. Avorn, and A.S. Kesselheim. 2015. Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. New England Journal of Medicine 372: 279\u2013286. https:\/\/doi.org\/10.1056\/NEJMhle1409465.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"9958_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1067\/mcp.2001.115446","volume":"69","author":"JA DiMasi","year":"2001","unstructured":"DiMasi, J.A. 2001. Risks in New Drug Development: Approval Success Rates for Investigational Drugs. Clinical Pharmacology and Therapeutics 69 (5): 297\u2013307. https:\/\/doi.org\/10.1067\/mcp.2001.115446.","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"9958_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi, J.A., H.G. Grabowski, and R.W. Hansen. 2016. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics 47: 20\u201333. https:\/\/doi.org\/10.1016\/j.jhealeco.2016.01.012.","journal-title":"Journal of Health Economics"},{"key":"9958_CR15","unstructured":"Doblin, R., and M. Mithoefer. 2015. Study Protocol, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness [Protocol MDA-1IND #63,384]. Accessed 28 November 2019, from https:\/\/maps.org\/research-archive\/mdma\/MDA-1_FINAL_Protocol_Amend%201_29Apr15_web.pdf."},{"issue":"2","key":"9958_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1467-8519.2006.00479.x","volume":"20","author":"SJL Edwards","year":"2006","unstructured":"Edwards, S.J.L. 2006. Restricted Treatments, Inducements, and Research Participation. Bioethics 20 (2): 77\u201391. https:\/\/doi.org\/10.1111\/j.1467-8519.2006.00479.x.","journal-title":"Bioethics"},{"key":"9958_CR17","doi-asserted-by":"publisher","unstructured":"Erritzoe, D., L. Roseman, M. M. Nour, K. MacLean, M. Kaelen, D. J. Nutt, and R. L. Carhart-Harris. 2018. Effects of Psilocybin Therapy on Personality Structure. Acta Psychiatrica Scandinavica 138 (5): 368\u2013378. https:\/\/doi.org\/10.1111\/acps.12904.","DOI":"10.1111\/acps.12904"},{"key":"9958_CR18","first-page":"293","volume-title":"Extraordinary science and psychiatry: Responses to the crisis in mental health research","author":"O Flanagan","year":"2017","unstructured":"Flanagan, O., and G. Graham. 2017. Truth and Sanity: Positive Illusions, Spiritual Delusions, and Metaphysical Hallucinations. In Extraordinary science and psychiatry: Responses to the crisis in mental health research, ed. J. Poland and S. Temkin, 293\u2013313. Cambridge: MIT Press."},{"issue":"3","key":"9958_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu, A., R.R. Griffiths, and M.W. Johnson. 2014. Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Current Drug Abuse Reviews 7 (3): 157\u2013164. https:\/\/doi.org\/10.2174\/1874473708666150107121331.","journal-title":"Current Drug Abuse Reviews"},{"issue":"1","key":"9958_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2014","unstructured":"Gasser, P., K. Kirchner, and T. Passie. 2014. LSD-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Disease: A Qualitative Study of Acute and Sustained Subjective Effects. Journal of Psychopharmacology 29 (1): 57\u201368. https:\/\/doi.org\/10.1177\/0269881114555249.","journal-title":"Journal of Psychopharmacology"},{"issue":"4A","key":"9958_CR21","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2007.02.002","volume":"120","author":"S Greenfield","year":"2007","unstructured":"Greenfield, S., R. Kravitz, N. Duan, and S.H. Kaplan. 2007. Heterogeneity of Treatment Effects: Implications for Guidelines, Payment, and Quality Assessment. The American Journal of Medicine 120 (4A): S3\u2013S9. https:\/\/doi.org\/10.1016\/j.amjmed.2007.02.002.","journal-title":"The American Journal of Medicine"},{"issue":"3","key":"9958_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths, R.R., W.A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance. Psychopharmacology (Berl) 187 (3): 268\u2013283. https:\/\/doi.org\/10.1007\/s00213-006-0457-5.","journal-title":"Psychopharmacology (Berlin)"},{"issue":"12","key":"9958_CR23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R.R., M.W. Johnson, M.A. Carducci, A. Umbricht, W.A. Richards, B.D. Richards, M.P. Cosimano, and M.A. Klinedinst. 2016. Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial. Journal of Psychopharmacology 30 (12): 1181\u20131197. https:\/\/doi.org\/10.1177\/0269881116675513.","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"9958_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths, R.R., M.W. Johnson, W.A. Richards, B.D. Richards, R. Jesse, K.A. MacLean, F.S. Barrett, M.P. Cosimano, and M.A. Klinedinst. 2018. Psilocybin-Occasioned Mystical-Type Experience in Combination with Meditation and other Spiritual Practices Produces Enduring Positive Changes in Psychological Functioning and in Trait Measures of Prosocial Attitudes and Behaviors. Journal of Psychopharmacology 32 (1): 49\u201369. https:\/\/doi.org\/10.1177\/0269881117731279.","journal-title":"Journal of Psychopharmacology"},{"key":"9958_CR25","doi-asserted-by":"publisher","unstructured":"Griffiths, R. R., E. S. Hurwitz, A. K. Davis, M. W. Johnson, and R. Jesse. 2019. Survey of Subjective \u201cGod Encounter Experiences\u201d: Comparisons among Naturally Occurring Experiences and those Occasioned by the Classic Psychedelics Psilocybin, LSD, Ayahuasca, or DMT. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0214377.","DOI":"10.1371\/journal.pone.0214377"},{"issue":"1","key":"9958_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob, C.S., A.L. Danforth, A.L. Chopra, A.M. Hagerty, C.R. McKay, A.L. Halberstadt, and andG. G. Greer. 2011. Pilot Study of Psilocybin Treatment for Anxiety in Patients with Advanced-Stage Cancer. Archives of General Psychiatry 68 (1): 71\u201378. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.116.","journal-title":"Archives of General Psychiatry"},{"key":"9958_CR27","doi-asserted-by":"publisher","unstructured":"Haijen, E. C. H. M., M. Kaelen, L. Roseman, C. Timmermann, H. Kettner, S. Russ, D. Nutt, R. E. Daws, A. D. G. Hampshire, R. Lorenz, and R. L. Carhart-Harris. 2018. Predicting Responses to Psychedelics: A Prospective Study. Frontiers in Pharmacology. https:\/\/doi.org\/10.3389\/fphar.2018.00897.","DOI":"10.3389\/fphar.2018.00897"},{"issue":"12","key":"9958_CR28","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","volume":"176","author":"TJ Hwang","year":"2016","unstructured":"Hwang, T.J., D. Carpenter, J.C. Lauffenburger, B. Wang, J.M. Franklin, and A.S. Kesselheim. 2016. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Internal Medicine 176 (12): 1826\u20131833. https:\/\/doi.org\/10.1001\/jamainternmed.2016.6008.","journal-title":"JAMA Internal Medicine"},{"issue":"6","key":"9958_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson, M.W., W. Richards, and R.R. Griffiths. 2008. Human Hallucinogen Research: Guidelines for Safety. Journal of Psychopharmacology 22 (6): 603\u2013620. https:\/\/doi.org\/10.1177\/0269881108093587.","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"9958_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson, M.W., and R.R. Griffiths. 2017. Potential Therapeutic Effects of Psilocybin. Neurotherapeutics 14 (3): 734\u2013740. https:\/\/doi.org\/10.1007\/s13311-017-0542-y.","journal-title":"Neurotherapeutics"},{"key":"9958_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson, M.W., P.S. Hendricks, F.S. Barrett, and R.R. Griffiths. 2019. Classic Psychedelics: An Integrative Review of Epidemiology, Therapeutics, Mystical Experience, and Brain Network Function. Pharmacology & Therapeutics 197: 83\u2013102. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.010.","journal-title":"Pharmacology & Therapeutics"},{"key":"9958_CR32","unstructured":"Jerome, L. 2007. Psilocybin: Investigator's Brochure [Unpublished]. Retrieved November 28, 2019 from https:\/\/maps.org\/research-archive\/psilo\/psilo_ib.pdf."},{"key":"9958_CR33","unstructured":"Jesse, R. 2001. On Nomenclature for the Class of Mescaline-Like Substances and Why It Matters. In Psychoactive sacramentals, essays on entheogens and religion, ed. T. B. Robert, 225\u2013231. San Francisco: Council on Spiritual Practices. Accessed 28 November 2019, from https:\/\/csp.org\/docs\/on-nomenclature."},{"issue":"2","key":"9958_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","volume":"235","author":"M Kaelen","year":"2018","unstructured":"Kaelen, M., B. Garibaldi, J. Raine, L. Evans, C. Timmermann, N. Rodriguez, L. Roseman, A. Feilding, D. Nutt, and R. Carhart-Harris. 2018. The Hidden Therapist: Evidence for a Central Role of Music in Psychedelic Therapy. Psychopharmacology (Berl) 235 (2): 505\u2013519. https:\/\/doi.org\/10.1007\/s00213-017-4820-5.","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"9958_CR35","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1002\/hbm.22833","volume":"36","author":"AV Lebedev","year":"2015","unstructured":"Lebedev, A.V., M. Lovden, G. Rosenthal, A. Feilding, D.J. Nutt, and R.L. Carhart-Harris. 2015. Finding the Self by Losing the Self: Neural Correlates of Ego-Dissolution under Psilocybin. Human Brain Mapping 36 (8): 3137\u20133153. https:\/\/doi.org\/10.1002\/hbm.22833.","journal-title":"Human Brain Mapping"},{"issue":"9\u201310","key":"9958_CR36","first-page":"170","volume":"22","author":"C Letheby","year":"2015","unstructured":"Letheby, C. 2015. The Philosophy of Psychedelic Transformation. Journal of Consciousness Studies 22 (9\u201310): 170\u2013193.","journal-title":"Journal of Consciousness Studies"},{"key":"9958_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.concog.2015.11.012","volume":"39","author":"C Letheby","year":"2016","unstructured":"Letheby, C. 2016. The Epistemic Innocence of Psychedelic States. Consciousness and Cognition 39: 28\u201337. https:\/\/doi.org\/10.1016\/j.concog.2015.11.012.","journal-title":"Consciousness and Cognition"},{"issue":"3","key":"9958_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/zygo.12353","volume":"52","author":"C Letheby","year":"2017","unstructured":"Letheby, C. 2017. Naturalizing Psychedelic Spirituality. Zygon 52 (3): 623\u2013642. https:\/\/doi.org\/10.1111\/zygo.12353.","journal-title":"Zygon"},{"key":"9958_CR39","doi-asserted-by":"publisher","DOI":"10.1057\/9781137528681","volume-title":"A Moral Defense of Recreational Drug Use","author":"R Lovering","year":"2015","unstructured":"Lovering, R. 2015. A Moral Defense of Recreational Drug Use. New York: Palgrave Macmillan. https:\/\/doi.org\/10.1057\/9781137528681"},{"issue":"5","key":"9958_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/02791072.2012.736842","volume":"44","author":"M Lyvers","year":"2012","unstructured":"Lyvers, M., and M.M. Honours. 2012. Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner. Journal of Psychoactive Drugs 44 (5): 410\u2013417. https:\/\/doi.org\/10.1080\/02791072.2012.736842.","journal-title":"Journal of Psychoactive Drugs"},{"issue":"7","key":"9958_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/0269881117748902","volume":"32","author":"T Lyons","year":"2018","unstructured":"Lyons, T., and R.L. Carhart-Harris. 2018. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of Psychopharmacology 32 (7): 811\u2013819. https:\/\/doi.org\/10.1177\/0269881117748902.","journal-title":"Journal of Psychopharmacology"},{"issue":"11","key":"9958_CR42","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"K MacLean","year":"2011","unstructured":"MacLean, K., M.W. Johnson, and R.R. Griffiths. 2011. Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness. J Psychopharmacol 25 (11): 1453\u20131461. https:\/\/doi.org\/10.1177\/0269881111420188.","journal-title":"J Psychopharmacol"},{"issue":"543","key":"9958_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1192\/bjp.118.543.229","volume":"118","author":"N Malleson","year":"1971","unstructured":"Malleson, N. 1971. Acute Adverse Reactions to LSD in Clinical and Experimental Use in the United Kingdom. British Journal of Psychiatry 118 (543): 229\u2013230. https:\/\/doi.org\/10.1192\/bjp.118.543.229.","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"9958_CR44","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1037\/h0037523","volume":"42","author":"R Matefy","year":"1974","unstructured":"Matefy, R., and R. Krall. 1974. An Initial Investigation of the Psychedelic Drug Flashback Phenomena. Journal of Consulting and Clinical Psychology 42 (6): 854\u2013860. https:\/\/doi.org\/10.1037\/h0037523.","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"3","key":"9958_CR45","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1037\/h0076876","volume":"43","author":"R Matefy","year":"1975","unstructured":"Matefy, R., and R. Krall. 1975. Psychedelic Drug Flashbacks: Psychotic Manifestations or Imaginative Role Playing? Journal of Consulting and Clinical Psychology 43 (3): 434. https:\/\/doi.org\/10.1037\/h0076876.","journal-title":"Journal of Consulting and Clinical Psychology"},{"key":"9958_CR46","volume-title":"Sacred Mushroom of Visions: Teonan\u00e1catl: A Sourcebook on thePsilocybin Mushroom","author":"R Metzner","year":"2005","unstructured":"Metzner, R. 2005. Sacred Mushroom of Visions: Teonan\u00e1catl: A Sourcebook on thePsilocybin Mushroom. Rochester: Park Street Press."},{"issue":"5","key":"9958_CR47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","volume":"3","author":"CM Mithoefer","year":"2016","unstructured":"Mithoefer, C.M., C.S. Grob, and T.D. Brewerton. 2016. Novel Psychopharmacological Therapies for Psychiatric Disorders: Psilocybin and MDMA. Lancet Psychiatry 3 (5): 481\u2013488. https:\/\/doi.org\/10.1016\/S2215-0366(15)00576-3.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"9958_CR48","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"CM Mithoefer","year":"2019","unstructured":"Mithoefer, C.M., S. Feduccia, L. Jerome, and A. Mithoefer. 2019. MDMA-AssistedPsychotherapy for Treatment of PTSD: Study Design and Rationale for Phase 3 Trials Based on Pooled Analysis of Six Phase 2 Randomized Controlled Trials. Psychopharmacology (Berlin) 236 (9): 2735\u20132745. https:\/\/doi.org\/10.1007\/s00213-019-05249-5.","journal-title":"Psychopharmacology (Berlin)"},{"key":"9958_CR49","unstructured":"Multidisciplinary Association for Psychedelic Studies. 2017. Press Release: FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Psychotherapy for PTSD, Agrees on Special Protocol Assessment for Phase 3 Trials [Blog Post]. August 26. Accessed 28 November 2019, from https:\/\/maps.org\/news\/media\/6786-press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd,-agrees-on-special-protocol-assessment-for-phase-3-trials."},{"key":"9958_CR50","unstructured":"Multidisciplinary Association for Psychedelic Studies. 2019. Statement: Public Announcement of Ethical Violation by Former Maps-Sponsored Investigators [Blog Post]. Accessed 25 November 2019, from https:\/\/maps.org\/news\/posts\/7749-statement-public-announcement-of-ethica-violation-by-former-maps-sponsored-investigators."},{"key":"9958_CR51","unstructured":"Multidisciplinary Association for Psychedelic Studies. 2020. FDA Agrees to Expanded Access Program for MDMA-Assisted Psychotherapy for PTSD [Press Release]. Accessed 21 April 2020, from https:\/\/maps.org\/news\/media\/8008-press-release-fda-agrees-to-expanded-access-program-for-mdma-assisted-psychotherapy-for-ptsd."},{"key":"9958_CR52","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols, D.E. 2016. Psychedelics. Pharmacological Reviews 68: 264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478.","journal-title":"Pharmacological Reviews"},{"issue":"3","key":"9958_CR53","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/02791072.2017.1312643","volume":"49","author":"MM Nour","year":"2017","unstructured":"Nour, M.M., L. Evans, and R.L. Carhart-Harris. 2017. Psychedelics, Personality and Political Perspectives. Journal of Psychoactive Drugs 49 (3): 182\u2013191. https:\/\/doi.org\/10.1080\/02791072.2017.1312643.","journal-title":"Journal of Psychoactive Drugs"},{"issue":"9","key":"9958_CR54","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.healthpol.2018.07.014","volume":"122","author":"J Pace","year":"2018","unstructured":"Pace, J., N. Ghinea, I. Kerridge, and W. Lipworth. 2018. An Ethical Framework for the Creation, Governance and Evaluation of Accelerated Access Programs. Health Policy 122 (9): 984\u2013990. https:\/\/doi.org\/10.1016\/j.healthpol.2018.07.014.","journal-title":"Health Policy"},{"key":"9958_CR55","volume-title":"Psycholytic and Psychedelic Therapy 1931\u20131995: A Complete International Bibliography","author":"T Passie","year":"1997","unstructured":"Passie, T. 1997. Psycholytic and Psychedelic Therapy 1931\u20131995: A Complete International Bibliography. Hannover: Laurentius Publishers."},{"key":"9958_CR56","unstructured":"Passie T., and P. Gasser 2016. Erfahrungen von Lebensbedrohlich Erkrankten in einer LSD-Unterst\u00fctzten Psychotherapie. Existenzanalyse 33 (2): 79\u201386. Retrieved Accessed 18 November 2019, from https:\/\/www.existenzanalyse.net\/wp-content\/uploads\/EA_2016_02.pdf."},{"issue":"4","key":"9958_CR57","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie, T., J. Seifert, U. Schneider, and H. Emrich. 2002. The Pharmacology of Psilocybin. Addiction Biology 7 (4): 357\u2013364. https:\/\/doi.org\/10.1080\/1355621021000005937.","journal-title":"Addiction Biology"},{"key":"9958_CR58","unstructured":"Pollan, M. 2015. The Trip Treatment. The New Yorker, February 9. Accessed 18 November 2019, from https:\/\/www.newyorker.com\/magazine\/2015\/02\/09\/trip-treatment."},{"key":"9958_CR59","doi-asserted-by":"publisher","unstructured":"Raus, K. 2016. An Analysis of Common Ethical Justifications for Compassionate Use Programs for Experimental Drugs. BMC Medical Ethics 17 (60). https:\/\/doi.org\/10.1186\/s12910-016-0145-x.","DOI":"10.1186\/s12910-016-0145-x"},{"issue":"2","key":"9958_CR60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1037\/bul0000088","volume":"143","author":"BW Roberts","year":"2017","unstructured":"Roberts, B.W., J. Luo, D.A. Briley, P.I. Chow, R. Su, and P.L. Hill. 2017. A Systematic Review of Personality Trait Change Through Intervention. Psychological Bulletin 143 (2): 117\u2013141. https:\/\/doi.org\/10.1037\/bul0000088.","journal-title":"Psychological Bulletin"},{"key":"9958_CR61","doi-asserted-by":"publisher","unstructured":"Roseman, L., D. Nutt, and R. Carhart-Harris. 2018. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Frontiers in Pharmacology. https:\/\/doi.org\/10.3389\/fphar.2017.00974.","DOI":"10.3389\/fphar.2017.00974"},{"issue":"12","key":"9958_CR62","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S., A. Bossis, J. Guss, G. Agin-Liebes, T. Malone, B. Cohen, S.E. Mennenga, A. Belser, K. Kalliontzi, J. Babb, Z. Su, P. Corby, and B.L. Schmidt. 2016. Rapid and Sustained Symptom Reduction Following Psilocybin Treatment for Anxiety and Depression in Patients with Life-Threatening Cancer: A Randomized Controlled Trial. Journal of Psychopharmacology 30 (12): 1165\u20131180. https:\/\/doi.org\/10.1177\/0269881116675512.","journal-title":"Journal of Psychopharmacology"},{"issue":"10001","key":"9958_CR63","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S0140-6736(15)00393-1","volume":"383","author":"R Rubin","year":"2015","unstructured":"Rubin, R. 2015. Experts Critical of America\u2019s Right-To-Try Drug Laws. The Lancet 383 (10001): 1325\u20131326. https:\/\/doi.org\/10.1016\/S0140-6736(15)00393-1.","journal-title":"The Lancet"},{"issue":"2","key":"9958_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1556\/2054.2019.008","volume":"3","author":"G Samorini","year":"2019","unstructured":"Samorini, G. 2019. The Oldest Archeological Data Evidencing The Relationship of Homo Sapiens with Psychoactive Plants: A Worldwide Overview. Journal of Psychedelic Studies 3 (2): 63\u201380. https:\/\/doi.org\/10.1556\/2054.2019.008.","journal-title":"Journal of Psychedelic Studies"},{"issue":"1","key":"9958_CR65","first-page":"28","volume":"16","author":"M Scheidegger","year":"2018","unstructured":"Scheidegger, M. 2018. Bewusstseinserweiternde Substanzen als neue M\u00f6glichkeiten der Therapie. InFo Neurologie & Psychiatrie 16 (1): 28\u201330.","journal-title":"InFo Neurologie & Psychiatrie"},{"issue":"3","key":"9958_CR66","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13311-017-0531-1","volume":"14","author":"B Sessa","year":"2017","unstructured":"Sessa, B. 2017a. Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist\u2019s Perspective. Neurotherapeutics 14 (3): 741\u2013749. https:\/\/doi.org\/10.1007\/s13311-017-0531-1.","journal-title":"Neurotherapeutics"},{"key":"9958_CR67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neuropharm.2017.11.004","volume":"142","author":"B Sessa","year":"2017","unstructured":"Sessa, B. 2017b. Why MDMA Therapy for Alcohol Use Disorder? And Why Now? Neuropharmacology 142: 83\u201388. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.11.004.","journal-title":"Neuropharmacology"},{"key":"9958_CR68","doi-asserted-by":"publisher","unstructured":"Sessa, B., L. Higbed, and D. Nutt. 2019. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Frontiers in Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2019.00138.","DOI":"10.3389\/fpsyt.2019.00138"},{"key":"9958_CR69","doi-asserted-by":"publisher","unstructured":"Simianu, V. V., M. A. Grounds, S. L. Joslyn, J. E. LeClerc, A. P. Ehlers, N. Agrawal, R. Alfonso-Cristancho, A. D. Flaxman, and D. R. Flum. 2016. Understanding Clinical and Non-Clinical Decisions Under Uncertainty: A Scenarion-Based Survey. BMC Medical Informatics and Decision Making. https:\/\/doi.org\/10.1186\/s12911-016-0391-3","DOI":"10.1186\/s12911-016-0391-3"},{"key":"9958_CR70","unstructured":"Sisti, D. 2018. Creating an Ethical Framework for Psychedelic Therapy Research. MAPS Bulletin 28 (3): 34\u201335. Accessed 28 November 2019, from https:\/\/maps.org\/news\/bulletin\/articles\/435-maps-bulletin-winter-2018-vol-28-no-3\/7505-maps-bulletin-winter-2018-vol-28,-no-3."},{"key":"9958_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-230-59394-7","volume-title":"Moral and Political Philosophy: Key Issues, Concepts, and Theories","author":"P Smith","year":"2008","unstructured":"Smith, P. 2008. Moral and Political Philosophy: Key Issues, Concepts, and Theories. New York: Palgrave Macmillan. https:\/\/doi.org\/10.1007\/978-0-230-59394-7"},{"issue":"11","key":"9958_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/15265161.2014.957416","volume":"14","author":"MJ Walker","year":"2014","unstructured":"Walker, M.J., W.A. Rogers, and V. Entwistle. 2014. Ethical Justifications for Access to Unapproved Medical Interventions: An Argument for (Limited) Patient Obligations. The American Journal of Bioethics 14 (11): 3\u201315. https:\/\/doi.org\/10.1080\/15265161.2014.957416.","journal-title":"The American Journal of Bioethics"},{"key":"9958_CR73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/pmj.78.920.319","volume":"78","author":"AF West","year":"2002","unstructured":"West, A.F., and R.R. West. 2002. Clinical Decision-Making: Coping with Uncertainty. Postgraduate Medical Journal 78: 319\u2013321. https:\/\/doi.org\/10.1136\/pmj.78.920.319.","journal-title":"Postgraduate Medical Journal"},{"key":"9958_CR74","unstructured":"World Health Organization. 2018. International Classification of Diseases for Mortality and Morbidity Statistics (11th Revision). Accessed 28 November 2019, from https:\/\/icd.who.int\/browse11\/l-m\/en#\/http:\/\/id.who.int\/icd\/entity\/932028588."},{"issue":"20","key":"9958_CR75","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. 2013. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 310 (20): 2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"issue":"2","key":"9958_CR76","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/cpt.565","volume":"101","author":"B Yazar-Klosinski","year":"2017","unstructured":"Yazar-Klosinski, B., and M. Mithoefer. 2017. Potential Psychiatric Uses for MDMA. Clinical Pharmacology and Therapeutics 101 (2): 194\u2013196. https:\/\/doi.org\/10.1002\/cpt.565.","journal-title":"Clinical Pharmacology and Therapeutics"}],"container-title":["Medicine, Health Care and Philosophy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11019-020-09958-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11019-020-09958-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11019-020-09958-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:55:53Z","timestamp":1778493353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11019-020-09958-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["9958"],"URL":"https:\/\/doi.org\/10.1007\/s11019-020-09958-z","relation":{},"ISSN":["1386-7423","1572-8633"],"issn-type":[{"value":"1386-7423","type":"print"},{"value":"1572-8633","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"28 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethcial standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}